ImevaX

Healthcare 📍 Munich, Germany 👥 11-50 employees 💰 $9.5M raised 📅 Founded 2014

ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany. The focus is to combat chronic and nosocomial infections by creating specific vaccines. The company’s lead candidate IMX 101 is a vaccine against Helicobacter pylori, which colonizes the stomach and is the cause of ulcer disease and gastric

🌐 Website in LinkedIn ← All Companies

📊 Company Overview

Sector

Healthcare

Country

Germany

Employees

11-50

Total Raised · Venture

$9.5M

Founded

2014

Cloud

Unknown

Email

Microsoft 365

☁️ Cloud Infrastructure

🔒 Subscribers only Cloud Provider

Workspace	Microsoft 365
CDN	🔒 Subscribers only

Detected via DNS records and HTTP response headers as of 2026-06-13.

💰 Estimated Cloud Spend

$108K – $270K / year across cloud providers

🛠 Tech Stack & Marketing

Ad Platforms	🔒 Subscribers only
Analytics & CRM	🔒 Subscribers only
CMS / Platform	Squarespace
Frontend Stack	🔒 Subscribers only

Detected from ImevaX's public homepage as of 2026-06-13.

🔍 Compare with Similar Companies

Same sector (Healthcare), similar size

1-10 ☁️ Unknown

Central Printing Group

1-10 ☁️ Unknown

Ortho Clinical Diagnostics Holdings Plc

1-10 ☁️ Azure

Data detected 2026-06-13 · Methodology · Suggest a correction